JSAM
CRNX icon

J. Safra Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

J. Safra Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13K Buy
358
+241
+206% +$10.8K ﹤0.01% 352
2025
Q4 		$5.45K Buy
117
+21
+22% +$935 ﹤0.01% 410
2025
Q3 		$4K Buy
96
+4
+4% +$128 ﹤0.01% 326
2025
Q2 		$2.65K Buy
92
+20
+28% +$618 ﹤0.01% 339
2025
Q1 		$2.42K Buy
72
+65
+929% +$2.43K ﹤0.01% 324
2024
Q4 		$355 Buy
+7
New +$392 ﹤0.01% 332

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

J. Safra Asset Management's CRNX Position: Q1 2026 in Review

J. Safra Asset Management increased its Crinetics Pharmaceuticals (CRNX) stake by 206% in Q1 2026, buying an estimated $10.8K and bringing the position to 358 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #352.

J. Safra Asset Management first reported a position in CRNX in Q4 2024 and has held it in 6 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • J. Safra Asset Management held 358 shares of Crinetics Pharmaceuticals worth $13K as of Q1 2026.
  • J. Safra Asset Management bought 241 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $10.8K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q1 2026, its #352 holding.
  • J. Safra Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.